As the prevalence of coronary artery disease (CAD) grows globally, interventional cardiologists are feeling the strain. With an ever-increasing case load and a squeeze on resources, delivering efficient, cost-effective and high-quality care presents significant challenges. At Philips, we also recognize that the cath lab is a complex landscape, made up of different information and systems. Philips offers a fully integrated ecosystem designed to meet today’s challenges and can provide you with more information faster. This enhances cath lab performance and which ultimately can support confident decisions and exceptional patient care. Moreover, our smart management of X-ray dosage is there to enhance patient care.
Philips coronary suite has advanced clinical and workflow applications, therapeutic and diagnostic devices, and leading services, all working together to efficiently support every step of coronary procedures. From diagnosis to restoring vessel patency, the coronary suite ecosystem is designed to enhance performance and efficiency today, while serving as your launching pad to the future:
Imagine if you could aggregate system performance data to improve departmental performance. Imagine if you could aggregate all patient cardio data to improve procedural decision making.
When you invest in Philips coronary suite, you are investing in a path to future technological advancements and capabilities. As we move from a mainly transactional to a value-based pathway in healthcare, integration, usability and artificial intelligence will drive the industry forward. It’s exciting to think of what’s possible when care providers can access the tools and technologies they need to create a fully integrated and transformed interventional cardiology service.
Experience the new world of interventional cardiac and vascular performance with the Azurion 7 series with 12'' flat detector.
The IntraSight applications platform is where imaging, physiology, co-registration1 and software all come together to clearly identify coronary and peripheral artery disease, and allow for more optimized treatment plans.
iFR is the gold standard among resting indices backed by patient outcomes that reduces costs, procedural time and patient discomfort2-4 while providing advance guidance with co-registration.
Our CAD solutions work together to help you provide quick, confident diagnosis, along with effective, efficient treatment – ultimately contributing to improved outcomes.
References
1 Co-registration tools available within IntraSight 7 configuration via SyncVision. 2 Patel M. “Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decisionmaking.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018. 3 Götberg M, Christiansen EH, Gudmundsdottir IJ, et al. iFR-SWEDEHEART Investigators. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017;376:1813-1823
4 Davies JE, Sen S, Dehbi HM, et al. Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017;376: 1824-1834.
You are about to visit a Philips global content page
Continue